The Catalyst

Most Recent Posts

01.27.15 | By John Castellani

We appreciate the opportunity to review the 21st Century Cures discussion draft released today and look forward to providing feedback to the House Energy and Commerce Committee.

PhRMA supports the Committee’s goal of accelerating the discovery, development and delivery of new medicines for patients and provided feedback on several of the 21st Century Cures whitepapers.

01.26.15 | By John Castellani

PhRMA supports Secretary Burwell’s goal of advancing affordable, high quality and patient centered health care, and today’s announcement represents an important step forward.

01.23.15 | By Christian Clymer

Now that 2015 is underway, it’s time to put our guiding principles into action. Our goal is to build on successes from 2014 to help patients live long, healthy lives. This week we started to put those plans into motion. We hope you’ll take an active interest in what we’re working on this year and share your thoughts with us.

01.22.15 | By Robert Zirkelbach

Developing innovative, lifesaving medicines for patients is the sole focus of the biopharmaceutical industry.

01.20.15 | By Robert Zirkelbach

When President Obama held his end-of-year press conference last month, he struck a clear and upbeat tone: “A new future is ready to be written. We've set the stage for this American moment.  And I'm going to spend every minute of my last two years making sure that we seize it.”

01.20.15 | By Robert Zirkelbach

In 2014, the FDA’s Center for Drug Evaluation and Research (CDER) approved a record 41 new medicines, making it a particularly strong year of innovation for America’s biopharmaceutical companies. This continues a trend in recent years towards a higher annual number of new medicines.  

01.15.15 | By Robert Zirkelbach

1-26-15 UPDATE: In response to the op-ed referenced below, The New York Times posted a Letter To The Editor from PhRMA President & CEO John Castellani.

01.09.15 | By Josephine Martin

By all accounts, 2014 presented a number of opportunities and challenges that highlighted just how important it is to keep the patient at the center of our ongoing efforts. It’s a notion that extends well beyond our industry, and should be a guiding principle as we head into 2015.

12.18.14 | By John Castellani

In 1989, while the world watched the Berlin Wall fall and history opened a new chapter, researchers in government and private labs half a world away were documenting a different beginning: the identification of the hepatitis C virus.

For the past 25 years, the resulting disease has remained largely incurable and often fatal for the world’s 170 million patients with the disease. Until now.

12.15.14 | By Allyson Funk

What if the information you need to make the most informed decision is not available?

12.11.14 | By Randy Burkholder

Today, I had the chance take part in a Google+ Hangout organized by TEDMED. A part of TEDMED’s Great Challenges series, the Hangout, titled, “A Delicate Balance: How Can We Rightsize Treatment Costs,?” was a lively discussion among stakeholders from across the health care ecosystem.

12.11.14 | By Jocelyn Ulrich

Setting the record straight about participation in clinical trials.

12.11.14 | By Mark Grayson

“When compounded products are not made according to strict quality standards appropriate for their scale of production, the results can be deadly.”  Six public health organizations wrote this to FDA Commissioner Hamburg to voice strong support on FDA’s robust enforcement of the federal law on compounding.

Principles on Conduct of Clinical Trials
12.10.14 | By Dr. Bill Chin

Researchers in biopharmaceutical companies strive to discover and develop new medicines and vaccines that will help people to live longer, healthier lives.  They go to work every day knowing that patients with life-threatening diseases live with the hope that tomorrow will bring a new medicine that will extend and improve lives.

12.05.14 | By Holly Campbell

Following several years of modest growth, a new study published in Health Affairs reports a record low health care spending increase of 3.6 percent in 2013. The last time the annual growth rate was any smaller, Dwight Eisenhower was President and a gallon of milk cost 49 cents.  The year was 1960.

Pages